ATE327767T1 - Verwendung einer emap-ii-rezeptor-antagonisten verbindung zur behandlung pulmonaler hypertension - Google Patents
Verwendung einer emap-ii-rezeptor-antagonisten verbindung zur behandlung pulmonaler hypertensionInfo
- Publication number
- ATE327767T1 ATE327767T1 AT01903010T AT01903010T ATE327767T1 AT E327767 T1 ATE327767 T1 AT E327767T1 AT 01903010 T AT01903010 T AT 01903010T AT 01903010 T AT01903010 T AT 01903010T AT E327767 T1 ATE327767 T1 AT E327767T1
- Authority
- AT
- Austria
- Prior art keywords
- emap
- pulmonary hypertension
- subject
- treatment
- receptor antagonist
- Prior art date
Links
- 102100022416 Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 Human genes 0.000 title abstract 3
- 108010000525 member 1 small inducible cytokine subfamily E Proteins 0.000 title abstract 3
- 208000002815 pulmonary hypertension Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 210000005166 vasculature Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17700800P | 2000-01-19 | 2000-01-19 | |
| US19749200P | 2000-04-17 | 2000-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE327767T1 true ATE327767T1 (de) | 2006-06-15 |
Family
ID=26872838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01903010T ATE327767T1 (de) | 2000-01-19 | 2001-01-10 | Verwendung einer emap-ii-rezeptor-antagonisten verbindung zur behandlung pulmonaler hypertension |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20010031738A1 (de) |
| EP (1) | EP1248641B1 (de) |
| AT (1) | ATE327767T1 (de) |
| AU (1) | AU3088501A (de) |
| CA (1) | CA2397733A1 (de) |
| DE (1) | DE60120111T2 (de) |
| WO (1) | WO2001052879A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040265238A1 (en) * | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
| US20050160023A1 (en) * | 2003-07-29 | 2005-07-21 | Mark Pearson | Systems and methods for consumers to purchase products |
| AU2005294265A1 (en) * | 2004-10-06 | 2006-04-20 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
| WO2007136617A2 (en) * | 2006-05-18 | 2007-11-29 | Walter Reed Army Institute Of Research (Wrair) | Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury |
| WO2009117680A2 (en) | 2008-03-20 | 2009-09-24 | Indiana University Research And Technology Corporation | Method for diagnosing and treating emphysema |
| US8980849B2 (en) * | 2010-04-16 | 2015-03-17 | Georgetown University | Compositions and methods for treating pulmonary hypertension |
| CN103687621A (zh) | 2011-06-08 | 2014-03-26 | 印第安纳大学研究与技术公司 | 用于诊断和治疗肺疾病和损伤的单克隆抗体和抗原 |
| WO2017070338A1 (en) * | 2015-10-20 | 2017-04-27 | Indiana University Research &Technology Corporation | Methods and compositions for treating lung disease of prematurity |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641867A (en) * | 1993-09-29 | 1997-06-24 | The Trustees Of Columbia University In The City Of New York | Antibody which specifically binds to endothelial-monocyte activating polypeptide II |
| AU776679B2 (en) * | 1998-11-13 | 2004-09-16 | Children's Hospital Of Los Angeles | Methods of facilitating vascular growth |
| US7537757B2 (en) * | 1999-12-23 | 2009-05-26 | Childrens Hospital Los Angeles | Methods of facilitating vascular growth in cardiac muscle and methods for the production of recombinant EMAP II |
-
2000
- 2000-12-15 US US09/738,685 patent/US20010031738A1/en not_active Abandoned
-
2001
- 2001-01-10 WO PCT/US2001/000748 patent/WO2001052879A1/en not_active Ceased
- 2001-01-10 AT AT01903010T patent/ATE327767T1/de not_active IP Right Cessation
- 2001-01-10 AU AU30885/01A patent/AU3088501A/en not_active Abandoned
- 2001-01-10 CA CA002397733A patent/CA2397733A1/en not_active Abandoned
- 2001-01-10 EP EP01903010A patent/EP1248641B1/de not_active Expired - Lifetime
- 2001-01-10 DE DE60120111T patent/DE60120111T2/de not_active Expired - Fee Related
-
2002
- 2002-10-21 US US10/274,788 patent/US7264803B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1248641A4 (de) | 2003-03-26 |
| EP1248641A1 (de) | 2002-10-16 |
| WO2001052879A1 (en) | 2001-07-26 |
| CA2397733A1 (en) | 2001-07-26 |
| DE60120111T2 (de) | 2006-12-07 |
| AU3088501A (en) | 2001-07-31 |
| US7264803B2 (en) | 2007-09-04 |
| EP1248641B1 (de) | 2006-05-31 |
| US20010031738A1 (en) | 2001-10-18 |
| US20030039652A1 (en) | 2003-02-27 |
| DE60120111D1 (de) | 2006-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200300834A1 (ru) | Антагонисты фактора, высвобождающего кортикотропин | |
| DE60137631D1 (de) | Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen | |
| ATE516819T1 (de) | Verfahren zur behandlung von b-zell-bedingtem krebs | |
| DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| ATE548025T1 (de) | Inhalierbare zubereitungen zur behandlung pulmonarer hypertensie und methoden zu ihrer verwendung | |
| ATE482213T1 (de) | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine | |
| WO2003037271A3 (en) | Compounds, pharmaceutical compositions and methods of use therefor | |
| ATE451376T1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| TR200200205T2 (tr) | MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi | |
| WO2005000244A3 (en) | Methods and compositions for treating rheumatoid arthritis | |
| NO20000521D0 (no) | 1-(N-fenylaminoalkyl)-piperazin derivater substituert i posisjon 2 på fenylringen | |
| ATE311200T1 (de) | Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten | |
| WO2002060392A3 (en) | Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
| ATE457177T1 (de) | Kombinationstherapie zur behandlung respiratorischer krankheiten mittels antikörper und anti-entzündungs wirkstoffe | |
| ATE348812T1 (de) | Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf) | |
| ATE327767T1 (de) | Verwendung einer emap-ii-rezeptor-antagonisten verbindung zur behandlung pulmonaler hypertension | |
| DE69935331D1 (de) | Verfahren und verbindungen zur behandlung der depression | |
| DE69831409D1 (de) | Chalcon-derivate mit antiproliferativer aktivität | |
| DE60329326D1 (de) | Tace inhibitoren | |
| DE69820066D1 (de) | Piperazinderivate zur behandlung der niedrigen harnwege | |
| DE60015791D1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| DE602006008583D1 (de) | Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung | |
| EA200601592A1 (ru) | Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора | |
| DE60230133D1 (de) | Toluolsulfonamid enthaltende antitumorale zusammensetzung und anwendungsverfahren dafür | |
| EA200300850A1 (ru) | Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |